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ABSTRACT 
This study investigates the utility of the Portuguese version of Montreal Cognitive Assessment 
(MoCA) as a screening-method for identifying cognitive dysfunction (CD) in multiple sclerosis (MS). 
The 118 participants with comprehensive neuropsychological assessment were divided into two 
subgroups: (I) MS group (n ¼ 59) and (II) control group (n ¼ 59). The MS patients were classified as 
cognitively intact (n ¼ 26) or impaired (n ¼ 33, 56%). The results indicated that the MoCA is a 
psychometrically valid instrument in assessment of MS patients. The Multiple Linear Regression 
analyses highlighted the significant influence of Modified Fatigue Impact Scale and Irregular Word 
Reading Test on MoCA performance. The MoCA total score showed a good discriminative capacity 
between cognitively impaired and cognitively intact subjects. In addition, there were significant 
differences in MoCA cognitive domain scores between groups. The MoCA total score cut-off point 
for identifying CD in MS patients was a score below 26 points (AUC ¼ 0.837, CI ¼ 0.736–0.937). 
A proposed EM-MoCA-Subscore for identifying the MS-related cognitive impairment (max. 
score ¼ 19 points, cut-off <17 points, AUC ¼ 0.871, CI ¼ 0.784–0.958), can reduce administration 
time for cognitive screening in clinical settings. The MoCA is a useful and sensitive instrument to 
identify the MS-related cognitive impairment. 
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Introduction 
Multiple Sclerosis (MS) is a chronic inflammatory 
demyelinating and degenerative disease of the central 
nervous system that primarily affects young adults 
(Hemmer, Nessler, Zhou, Kieseier, & Hartung, 2006). 
In the last few decades, cognitive dysfunction (CD) 
has been recognized as a common and early manifes-
tation of MS, with reported prevalence rates of between 
40 and 70% of patients (Amato, Zipoli, & Portaccio, 
2006). CD has a remarkably negative impact on func-
tionality, compromising employment status, social 
activities, treatment adherence, and quality of life 
(Langdon, 2011). 
The pattern of MS-related CD is well characterized, 
and rather than presenting as a global impairment, it 
is typically confined to specific cognitive domains: 
information processing speed, episodic memory and 
executive function (Strober et al., 2009). Nevertheless, 
there is some degree of inter-patient variability due to 
the heterogeneous pathological substrates of MS and 
individual cognitive reserves (Sumowski, Wylie, 
Chiaravalloti, & DeLuca, 2010), which make more 
challenging and complex the cognitive evaluation in this 
clinical population. 
CD is found in all disease stages but may be disso-
ciated from physical disability, and patients may not 
be fully aware of their cognitive deficits (Langdon 
et al., 2012). A comprehensive neuropsychological 
evaluation is time-consuming, expensive, and requires 
well-trained professionals, thus hindering its use in 
clinical settings. Furthermore, the MS-related fatigue 
can also be an impediment for administering extensive 
assessment batteries. The most common neuropsycho-
logical batteries that have been validated for use in 
MS patients are the 45-min Brief Repeatable Battery of 
Neuropsychological tests (BRB-N) (Rao & Cognitive 
Function Study Group of the National Multiple 
Sclerosis Society, 1990) and 90-min Minimal Assess-
ment of Cognitive Function in MS (MACFIMS) 
(Benedict et al., 2006). Recently, a Brief International 
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Assessment of Cognition for MS (BICAMS) has been 
proposed by an expert consensus committee of 
neurologists and neuropsychologists (Langdon et al., 
2012). The battery comprises the Symbol Digit 
Modalities Test, California Verbal Learning Test - II 
(first five recall trials), and Brief Visuospatial Memory 
Test - Revised (first three recall trials). However, even 
though its validation is currently under development 
in different languages and countries, the process has 
been completed only in a few countries (Dusankova, 
Kalincik, Havrdova, & Benedict, 2012; Eshaghi et al., 
2012; Giedraitienė, Kizlaitienė, & Kaubrys, 2015; Goretti 
et al., 2014; O’Connell, Langdon, Tubridy, Hutchinson, 
& McGuigan, 2015; Sandi et al., 2015; Spedo et al., 2015; 
Walker et al., 2016) and therefore is not yet worldwide 
available for use in clinical practice. Furthermore, some 
instruments have been recommended for the screening 
of CD in MS patients, namely the Symbol Digit 
Modalities Test (SDMT; Rao, 1991; Smith, 1982), with 
reported high sensitivity (.91) but poor specificity 
(.60) (Van Schependom et al., 2014) and good reliability 
in monitoring cognitive function over time (Morrow 
et al., 2010). Finally, the Mini Mental State Examination 
(MMSE; Folstein, Folstein, & McHugh, 1975) is widely 
used, although it does not give appropriate screening 
measures of cognitive impairment in MS (Benedict 
et al., 2008). As widely reported, the MMSE is not an 
adequate measure for milder forms of cognitive impair-
ment because the high probability of false negatives 
cases, which is especially critical under the emphasis 
placed upon the early detection of cognitive impairment 
and its impact on treatment and respective course of 
disease. This lack of sensitivity results from the low 
complexity of the tasks for assessment of memory, 
language and visuospatial dysfunctions and from the 
lack of tasks for the evaluation of executive function 
(Freitas, Simões, Alves, Duro, & Santana, 2012; Naugle 
& Kawczak, 1989), which can compromise the detection 
of MS-related cognitive impairment. The Montreal 
Cognitive Assessment (MoCA; Nasreddine et al., 
2005) overcomes these well-known limitations of the 
MMSE. In this context, a brief screening instrument 
that evaluates the most important cognitive domains 
would be extremely valuable, covering both the detec-
tion of MS-related cognitive impairment and evolution 
monitoring in everyday clinical practice. 
The MoCA is a screening instrument which allows a 
global cognitive measurement to be made through the 
assessment of a wide range of cognitive functions, such 
as (i) short-term memory, (ii) executive functions, (iii) 
visuospatial abilities, (iv) language, (v) attention, 
concentration and working memory, and (vi) temporal 
and spatial orientation (Nasreddine et al., 2005). The 
MoCA has been shown to be a sensitive tool for milder 
states of cognitive impairment, not only in the spectrum 
of Mild Cognitive Impairment (MCI) and Alzheimer’s 
disease (AD) (Freitas, Simões, Alves, & Santana, 2013; 
Nasreddine et al., 2005; Roalf et al., 2013) but also for 
cognitive impairment associated with many other clini-
cal conditions [e.g., vascular cognitive impairment 
(Pendlebury, Cuthbertson, Welch, Mehta, & Rothwell, 
2010), Parkinson’s Disease (Hoops et al., 2009), 
Huntington’s Disease (Videnovic et al., 2010), and 
tumors (Olson et al., 2010)]. These results, which are 
consistently good as a measure of global cognitive 
function, have led to the widespread use of the MoCA 
in both clinical and research contexts. Its extensive vali-
dation, international recognition and recommendation 
in various guidelines make it a useful brief cognitive 
screening tool (Arnold et al., 2007; Gauthier et al., 
2011; Hachinski et al., 2006). 
The few published studies on the MoCA in MS seem 
to corroborate its usefulness as a brief screening instru-
ment for the detection of cognitive impairment in MS 
patients. Two independent studies found convergent 
results, demonstrating that the MoCA cognitive perfor-
mance of MS patients was significantly lower than 
the performance of normal subjects, with major 
deterioration in the language, memory, attention, and 
executive domains of the MoCA (Abraham & Rege, 
2012; Aksoy et al., 2013). Dagenais et al. (2013) 
observed significant differences in the MoCA total score 
between cognitively intact and cognitively impaired MS 
patients, and significant correlations between scores in 
MoCA domains and the corresponding factors derived 
from the comprehensive neuropsychological assess-
ment. Finally, Kaur, Kumar, and Singh (2013) also 
examined the MoCA and its 5-minute protocol 
(Hachinski et al., 2006) in MS patients, concluding that 
both MoCA versions were effective in detecting CD in 
this group. This allows the short version to be adminis-
tered when there is underlying visual or motor disability 
in these patients. Overall, none of these studies exam-
ined the diagnostic accuracy of the MoCA for detecting 
CD in MS, nor were cut-off points for this purpose 
clearly defined. 
In the last few years, the MoCA has been the subject 
of a systematic investigation plan within the Portuguese 
population. After the normative study (Freitas, Simões, 
Alves, & Santana, 2011), various validation studies were 
conducted. Some of these studies further emphasize the 
psychometric characteristics of the instrument (e.g., 
Freitas, Simões, Marôco, Alves, & Santana, 2012; Freitas, 
Prieto, Simões, & Santana, 2014), while others primarily 
focus on specific clinical groups [e.g., vascular dementia 
(Freitas, Simões, Alves, Vicente, & Santana, 2012)]. The 
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present study was undertaken with the aim of further 
validating the MoCA’s Portuguese version for a brief 
assessment of CD in MS patients. This was carried out 
through the analysis of its psychometric properties, 
investigation of the influence of sociodemographic 
variables on MoCA performance, exploration of the 
cognitive performances of this clinical group, analysis 
of its diagnostic accuracy and establishment of the 
optimal cut-off point for detecting CD in MS patients. 
To date, and as far as we know, there have been no 
other validation studies proposing a cut-off point for 
identifying the cognitive clinical alterations in MS 
patients and examining the respective diagnostic accu-
racy of the MoCA. This represents a considerable gap 
in the full validation of this instrument and significantly 
limits its usefulness in clinical practice. 
Method 
Participants and procedures 
The study sample was composed of 118 participants 
divided into two subgroups: (I) the MS group with 
59 patients and (II) the control group with 59 cogni-
tively healthy adults. 
The MS patients were recruited consecutively 
between January 2012 and December 2013 from fol-
low-up consultations at the Neurology Department of 
a central hospital. The diagnosis of MS had been estab-
lished by a team of highly trained neurologists (SB and 
LS) according to the revised 2010 McDonald criteria 
(Polman et al., 2012). For this study we only recruited 
MS patients with Relapsing-Remitting or Secondary- 
Progressive forms of the disease, aged between 18 and 
55 years, and in a stable condition (no relapses or ster-
oid pulse treatment for 8 weeks preceding evaluation). 
The primary progressive MS and progressive relapsing 
MS cases were not included in the study sample since 
these other subtypes represent a minority of MS patients 
and some studies have shown them to be cognitively 
distinct from the other subtypes (Ruet, Deloire, 
Charré-Morin, Hamel, & Brochet, 2013). 
The healthy group was composed of cognitively 
healthy community members voluntarily recruited from 
a convenience sample, without developmental delays or 
other major medical disorders that may compromise 
cognitive function. All participants performed normally 
in the neuropsychological assessment battery compiled 
for this study, taking into account the Portuguese- 
validated data. These volunteer participants were 
further selected in order to match each patient regard-
ing gender and variables that were found to be predic-
tive of the MoCA’s performance (educational level 
and age; Freitas, Simões, Alves, Duro, et al., 2012). 
The following exclusion criteria were considered for 
the eligibility of both groups: (I) the absence of 
Portuguese language skills adequate for cognitive test-
ing; (II) a current or past history of neurological disease 
(other than MS for the study group), traumatic brain 
injury or psychiatric disorder, including depression; 
(III) previous or current alcohol abuse or other sub-
stance abuse; (IV) severe visual or auditory impairment 
that would negatively affect the ability to satisfactorily 
complete tests or understand test instructions; or 
(V) current or prior use of antipsychotic medication. 
Informed consent was obtained from all the 
participants after the research aims, procedures, and 
confidentiality requirements were fully disclosed by a 
member of the research team. The present research 
complied with the ethical guidelines for human 
experimentation stated in the Declaration of Helsinki 
and was approved by the Ethics Board and Scientific 
Committee of the affiliated Portuguese institutions. 
Materials and neuropsychological assessment 
The same psychologist (AA), with expertise in neurop-
sychological assessment and blinded to the cognitive 
status of the participants administered the MoCA 
(Nasreddine et al., 2005; Simões et al., 2008) to all 
participants. The clinical interview and neurologic 
examination were performed by one of the neurologists 
(SB). Demographic and clinical data were collected 
through a complete sociodemographic questionnaire 
and an inventory of past habits, current clinical health 
status and medical history. For the MS patients, we also 
considered relevant clinical data, namely disease sub-
type classification, age of disease onset, age at diagnosis, 
disease duration and current disease-modifying 
treatment. Physical disability was evaluated using the 
detailed Kurtzke Expanded Disability Status Scale 
(EDSS; Kurtzke, 1983). 
All study participants were investigated with a 
comprehensive neuropsychological assessment battery 
administered in a fixed order, and which included the 
following instruments: the Symbol Digit Modalities Test, 
Rao adaptation (SDMT) – as a measure of visual 
information-processing speed (Rao, 1991; Smith, 
1982); the Paced Auditory Serial Addition Test, Rao 
adaptation (PASAT) – as a measure of auditory 
information-processing speed and working memory 
(Gronwall, 1977); the Brief Visuospatial Memory Test- 
Revised (BVMT) – for the evaluation of visuospatial 
learning and memory (Benedict, 1997); the California 
Verbal Learning Test (CVLT) – for the assessment of 
verbal episodic learning and memory (Delis, Kramer, 
Kaplan, & Ober, 1987); the Judgment of Line Orientation 
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Test (JLO) – to assess spatial perception (Benton, Sivan, 
Hamsher, Varney, & Spreen, 1994); and to evaluate 
executive functions: the Stroop Test (ST; Golden & 
Freswater, 2002), the Trail Making Test A and B 
(TMT-A and TMT-B; War Department Adjutant 
General’s Office, 1944), the Verbal Fluency Test (VFT; 
Rosen, 1980) and the Raven’s Advanced Progressive 
Matrices (RAPM; Raven, Court, & Raven, 1983). 
Portuguese translations of the neuropsychological tests 
were used. The process of translating these tests into 
our language and adapting them to our cultural context 
followed the guidelines proposed in the literature 
(Hambleton, 2005; Hambleton & Patsula, 1999; 
Herdman, Fox-Rushby, & Badia, 1998; International 
Test Commission, 2001; Vijver & Poortinga, 2005). 
We considered the following criteria to define cogni-
tive impairment, as reported previously in other studies 
(Benedict et al., 2004; Batista et al., 2012): a) a z score of 
<–1.5 across four tests, or b) the presence of one severe 
(z <   2.0) and two mild (z <   1.5) cognitive defects, or 
c) two severe defects (z <  2.0), across all cognitive 
measures of the neuropsychological assessment battery 
compiled for this study, excluding the MoCA (target 
tool of the study). 
Additionally, the patients were assessed using the 
following scales: the Irregular Word Reading Test 
(TeLPI) – to estimate premorbid intelligence levels 
(Alves, Simões, & Martins, 2009); the Beck Depression 
Inventory (Vaz Serra & Pio Abreu, 1973a, 1973b) and 
Modified Fatigue Impact Scale (MFIS; Fisk, Pontefract, 
Ritvo, Archibald, & Murray, 1994; Gomes, 2011): to 
evaluate depression and fatigue, respectively, as these 
factors are known to influence cognition. 
As the MoCA is the target tool of this study, the 
following is a more detailed description of this neurop-
sychological instrument. The MoCA (Nasreddine et al., 
2005; Simões et al., 2008) is a brief cognitive screening 
instrument developed to screen milder forms of cogni-
tive impairment, allowing the global cognitive state to 
be ascertained rapidly. The MoCA comprises a one- 
page test, which can be administered quickly (in 10 to 
15 minutes), and a manual with explicit instructions 
for administering the tasks and an objective presen-
tation of the defined scoring system. A total score is 
generated through the sum of the points of each suc-
cessfully completed task, in a range from 0 to 30 points, 
with higher scores indicating better cognitive perfor-
mance. In the present study, the MoCA was not used 
as a diagnostic tool and the MoCA total score refers 
to the raw score without correction for the educational 
effects proposed in the original study (Nasreddine et al., 
2005), because this correction point is not used in the 
Portuguese population (Freitas et al., 2011). The cultural 
adaptation of the MoCA to the Portuguese population 
involved translation, linguistic improvement of the 
instrument and manual, studies with the experimental 
version, further revision and adjustments to finalize 
the Portuguese version, and an analysis of the equival-
ence of this version to the original (at six levels: concep-
tual, by item, semantic, operational, by measurement, 
and functional) (Freitas et al., 2010). 
Statistical analysis 
Statistical analyses were conducted using the Statistical 
Package for the Social Sciences (SPSS, version 20.0; 
IBM SPSS, Chicago, IL). Descriptive statistics were used 
to characterize the sample. The v2 test and the two- 
sample t-test allowed the two groups to be compared, 
while the effect size was estimated using Cohen’s d 
(Cohen, 1988). Cronbach’s alpha was considered as an 
index of internal consistency, and Pearson’s correlation 
coefficients were used to assess the convergent validity 
(between the MoCA total scores and instruments of 
the neuropsychological battery assessment) and as an 
indicator of construct-related validity (between each 
item and the cognitive domains, between cognitive 
domains, and between each cognitive domain and the 
MoCA total score). 
To investigate the significance of: age (in years), edu-
cation (years of schooling successfully completed), BDI, 
MFIS, and premorbid intelligence (TeLPI score) as 
influencing factors in the MoCA, Multiple Linear 
Regression (MLR) analyses were performed using the 
Enter method (the standard method of simultaneous 
entry, where all independent variables enter the equa-
tion at the same time). Multicollinearity was examined 
through Tolerance and Variance Inflation Factor 
(VIF) statistics (Tolerance of less than 0.40 and/or a 
VIF of 2.5 or above indicates a multicollinearity 
problem - Meyers, Gamst, & Guarino, 2006), and the 
coefficient of determination (Adjusted R2) was con-
sidered in the analysis of effect size in the regressions 
(Cohen, 1988). 
Z scores were calculated by (patient’s score - mean 
value of control group matched for age, sex, and edu-
cation level)/standard deviation of the control group. 
The MoCA scores differences between the MS 
subgroups, considering the influence of age and edu-
cation, was addressed with the analysis of covariance 
(ANCOVA). Eta squared (g2) was used as an estimate 
of the effect size and g2p values of .01, .06 and .14 are 
considered small, medium and large effect sizes, 
respectively (Cohen, 1988). 
The diagnostic accuracy of the MoCA for predicting 
cognitively impaired MS patients was assessed through 
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the receiver operating characteristics (ROC) curve 
analysis. The area under the curve (AUC) was calcu-
lated, which can vary between 0.5 and 1, with a larger 
AUC signifying better diagnostic accuracy. The optimal 
cut-off point that yielded the highest Youden index was 
selected, with a higher index indicating the maximiza-
tion of the instrument’s sensitivity and specificity. To 
analyze the predictive value of the test for this optimal 
cut-off point, we calculated the sensitivity (the prob-
ability that subjects with cognitive impairment will test 
positive), specificity (the probability that subjects with-
out cognitive impairment will test negative), positive 
predictive value (PPV ¼ the probability of disease in 
subjects who test positive), negative predictive value 
(NPV ¼ the probability of a lack of cognitive impair-
ment in subjects who test negative) and classification 
accuracy (the probability of correctly classifying subjects 
who either do or do not have cognitive impairment). 
Results 
Sociodemographic, clinical and cognitive 
characterization of subgroups 
The sociodemographic characteristics of the study 
sample, including details of the subgroups, are pre-
sented in Table 1. For this description, the following 
parameters were considered: sample size, gender, age 
and educational level. In the MS study group, patients 
presented an average age of disease onset and diagnosis 
of, respectively, 26.83 � 7.81 years and 29.31 �
7.70 years, corresponding to an average time for the 
establishment of diagnosis of 2.47 � 3.82 years. These 
patients had a mean disease duration of 10.39 � 6.55 
years, EDSS median of 2.0 (mean ¼ 2.50 � 1.42), 
approximately 86% had a Relapsing-Remitting and 
14% a Secondary Progressive disease course subtype. 
Table 2 summarizes the cognitive features of subgroups, 
taking into account the results of the neuropsychologi-
cal assessment battery compiled for this study. 
As previously mentioned, the control participants 
were matched for gender, age, and educational level 
with the MS patients. Because of this, there were 
no gender differences between the two groups 
(v2
ð1Þ ¼ 0:000, p ¼ 1.0). Likewise, no statistically signifi-
cant differences were found based on age (t(115) ¼ 0.798, 
p ¼ 0.427) or educational level (t(178) ¼ 1.282, 
p ¼ 0.202). 
Psychometric properties 
The internal consistency of the MoCA was estimated 
using Cronbach’s a. In the total sample (N ¼ 118), we 
found a Cronbach’s a of 0.65. This coefficient was also 
computed for the MS group (n ¼ 59), where the respect-
ive value was 0.61. A more detailed analysis revealed 
that there was no improvement regarding the 
Cronbach’s a value with the exclusion of any item of 
the scale. 
As indicators of convergent validity, we found stat-
istically significant correlation coefficients between the 
MoCA total scores and the scores in the neuropsycholo-
gical battery assessment instruments, with coefficient 
values ranging between 0.35 and 0.59 (p < 0.01) in the 
total sample and between 0.31 and 0.62 (p < 0.01) in 
the MS group, as presented on Table 3. 
In the MS group, we also analyzed the correlations 
between each MoCA item and the MoCA cognitive 
domains, between MoCA cognitive domains, and 
between each MoCA cognitive domain and the MoCA 
total score. All of the items showed a stronger corre-
lation with their respective domains than with any other 
domain. In addition, we found a significant positive cor-
relation between each cognitive domain and the total 
score of the scale, ranging from 0.43 to 0.63 (p < 0.01). 
Furthermore, each domain showed stronger correla-
tions with the MoCA total score than with any other 
domain, which illustrates the discriminative power of 
the MoCA cognitive domains. 
Influence factors on MoCA performance 
Considering only the MS group, we did not find any 
statistically significant differences in MoCA scores 
between gender groups (t(57) ¼ 0.579, p ¼ 0.565) and 
age groups [three subgroups were considered: 
<30 years, 30–40 years and >40 years (F(2,58) ¼ 2,036, 
Table 1. Sociodemographic characteristics of the total sample and subgroups.  
MS group MS intact group MS impaired group Control group Total sample  
n/N 59 26 33 59 118 
Gender  
F (%) 39 (66.1) 19 (73.1) 20 (60.6) 39 (66.1) 78 (66.1) 
Age  
M � SD [Min.-Max.] 37.20 � 7.58 [22–54] 33.77 � 6.92 [22–53] 39.91 � 7.03 [28–54] 36.03 � 9.52 [21–55] 36.62 � 8.59 [21–55] 
Education  
M � SD [Min.-Max.] 13.22 � 4.01 [4–19] 15.15 � 2.91 [8–19] 11.70 � 4.13 [4–19] 14.12 � 3.86 [6–21] 13.67 � 3.94 [4–21] 
Note. F ¼ feminine gender; M ¼mean; SD ¼ standard deviation; Min. ¼minimum value; Max. ¼maximum value.   
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6 
p ¼ 0.140). Education, defined as years of schooling suc-
cessfully completed, was the sociodemographic variable 
with the greatest influence on MoCA results, with 
higher performances in the more educated groups 
[three subgroups were considered: Primary to Middle 
(<9 years of schooling), High (10–12 years of school-
ing) and University (>12 years of schooling); 
(F(2,58) ¼ 4.705, p ¼ 0.013). 
The MoCA total score showed statistical significant 
correlation (p < 0.01) with the educational level 
(r ¼ 0.33), MFIS (r ¼   0.39) and TeLPI (r ¼ 0.44), 
whereas no significant coefficients were founded with 
age and BDI scores. 
To examine the contributions of age, education level, 
BDI, MFIS and TeLPI scores in explaining the variance 
in MoCA scores, an MLR analysis was performed using 
the Enter method. This analysis resulted in a significant 
regression model (F(1,58) ¼ 6.740, p < 0.001) in which 
all variables together explain 33% of total variance in 
the MoCA scores (Adjusted R2 ¼ 0.331). Table 4 pre-
sents the significance of each factor in the regression 
model, the Tolerance and VIF values and partial 
correlations. 
Group differences 
The MS patients were classified as cognitively intact or 
cognitively impaired according to their performance in 
the comprehensive neuropsychological assessment bat-
tery compiled for this study, excluding the MoCA. In 
this study sample, approximately 56% (n ¼ 33) of all 
MS patients showed cognitive impairment, while 44% 
(n ¼ 26) had a normal global cognitive performance, 
according to the above criteria. 
A comparison of all three groups: cognitively 
impaired MS group, cognitively intact MS group and 
control group showed the existence of statistically 
significant differences between the groups (F(1,118) ¼
11.962, p < 0.001, g2p ¼ 0:175) in the MoCA total scores 
as well as in several domains: short-term memory 
(F(1,118) ¼ 11.200, p < 0.001, g2p ¼ 0:178), executive 
functions (F(1,118) ¼ 3.502, p ¼ 0.033, g2p ¼ 0:058), and 
temporal and spatial orientation domains (F(1,118) ¼
5.091, p ¼ 0.008, g2p ¼ 0:083), controlling for the effect 
of covariates age and educational level [since statistically 
significant differences were observed in mean age 
(F(2,117) ¼ 4.210, p ¼ 0.017) and mean educational level 
(F(2,117) ¼ 7.011, p ¼ 0.001) between the groups but no 
gender differences (v2
ð2Þ ¼ 1:060, p ¼ 0.588)]. 
MS group versus control group 
A comparative analysis between the clinical and control 
groups revealed statistically significant differences in the 
MoCA total scores (t(116) ¼ 3.768, p < 0.001, d ¼ 0.69), 
with a lower performance for the MS patients (25.03 �
2.51; control group: 26.76 � 2.44). With regard to the 
subscores in MoCA cognitive domains, the two groups 
showed statistically significant differences in the 
executive functions (t(116) ¼ 2.710, p ¼ 0.008), language 
(t(116) ¼ 2.338, p ¼ 0.021), and short-term memory 
domains (t(116) ¼ 3.813, p < 0.001). 
Cognitively impaired MS versus cognitively  
intact MS 
The MS subgroups, showed statistically significant 
differences in mean age [t(57) ¼ 3.358, p ¼ 0.001; with 
the cognitively intact patients being younger (33.77 �
6.92) than the cognitively impaired patients (39.91 �
7.03)] and mean educational level [t(57) ¼ 3.765, 
Table 3. Correlation coefficients between the MoCA and the 
neuropsychological battery assessment instruments.  
MoCA total scores  
MS group Total sample  
Symbol Digit Modalities Test, Rao adaptation 
(SDMT)  
0.61  0.50 
Paced Auditory Serial Addition Test, Rao 
adaptation (PASAT)  
0.58  0.53 
Brief Visuospatial Memory Test- Revised    
Total Learning (BVMT-R-TL)  0.50  0.50  
Delayed Recall (BVMT-R-DR)  0.52  0.54 
California Verbal Learning Test (CVLT)    
Total Learning (CVLT-TL)  0.50  0.53  
Delayed Recall (CVLT-DR)  0.45  0.45 
Judgment of Line Orientation Test (JLOT)  0.54  0.53 
Stroop Test  
Color (ST-C)    0.37    0.35  
Color -Word (ST-CW)    0.54    0.43 
Trail Making Test A (TMT-A)    0.31    0.38 
Trail Making Test B (TMT-B)    0.54    0.56 
Verbal Fluency Test (VFT)  0.42  0.37 
Raven’s Advanced Progressive Matrices 
(RAPM)  
0.62  0.52 
Irregular Word Reading Test (TeLPI)  0.44  0.46 
Number of impaired scores on the battery 
assessment instruments  
0.62  0.59 
Note. All correlation coefficients are significant at the 0.01 level. The criterion 
for impaired score on the neuropsychological battery assessment 
instruments was z < -1.5.   
Table 4. Regression model.  
Contribution to the Model Tolerance VIF Partial Correlations  
Age ß ¼   0.126, t ¼ 1.171, p ¼ 0.247  0.956  1.047    1.59 
Education ß ¼ 0.127, t ¼ 1.038, p ¼ 0.304  0.768  1.303  0.141 
BDI ß ¼ 0.152, t ¼ 1.086, p ¼ 0.282  0.588  1.699  0.148 
MFIS ß ¼   0.454, t ¼ 3.242, p ¼ 0.002  0.589  1.697    0.407 
TeLPI ß ¼ 0.363, t ¼ 3.000, p ¼ 0.004  0.790  1.266  0.381  
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p < 0.001; with the cognitively intact patients presenting 
a higher educational level (15.15 � 2.91) than the cogni-
tively impaired patients (11.70 � 4.13)]. Controlling for 
the effect of these variables, no statistically significant 
differences were found in average age of onset, average 
age at diagnosis, average time taken to establish a diag-
nosis, the mean disease duration, the physical disability 
measured by the EDSS or the depressive symptoma-
tology as measured by the BDI. Regarding the measure 
of fatigue, cognitively impaired MS patients presented 
significantly higher MFIS total scores (F(1,55) ¼ 9.363, 
p ¼ 0.003, g2p ¼ 0:145). 
Controlling for the effect of covariates (age and 
educational level), we found statistically significant 
differences in the MoCA total scores (F(1,55) ¼ 15.229, 
p < 0.001, g2p ¼ 0:217) between the cognitively intact 
(26.58 � 1.82) and cognitively impaired MS group 
(23.70 � 2.31); and regarding the MoCA cognitive 
domain subscores the two groups showed statistically 
significant differences in the executive functions 
(F(1,55) ¼ 4.321, p ¼ 0.042, g2p ¼ 0:073), visuospatial 
(F(1,55) ¼ 5.749, p ¼ 0.020, g2p ¼ 0:095), short-term 
memory (F(1,55) ¼ 8.354, p ¼ 0.005, g2p ¼ 0:132), and 
temporal and spatial orientation domains (F(1,55) ¼
4.045, p ¼ 0.049, g2p ¼ 0:069). 
Cognitively impaired MS versus control group 
There were statistically significant differences between 
groups in the MoCA total scores (F(1,88) ¼ 21.939, 
p < 0.001, g2p ¼ 0:200) as well as in several domains: 
short-term memory (F(1,88) ¼ 22.189, p < 0.001, 
g2p ¼ 0:201), executive functions (F(1,88) ¼ 6.187, 
p ¼ 0.015, g2p ¼ 0:066), and temporal and spatial orien-
tation domains (F(1,88) ¼ 7.471, p ¼ 0.008, g2p ¼ 0:078), 
considering the control for the effect of covariates (age 
and educational level). 
Cognitively intact MS versus control group 
A comparative analysis between the cognitively intact 
MS patient group and the control group revealed no 
statistically significant differences in MoCA total scores 
(F(1,81) ¼ 1.757, p ¼ 0.189) or in any of the MoCA’s 
cognitive domains, considering the control for the effect 
of covariates (age and educational level). 
Cut-off points and diagnostic validity 
Several ROC curve analyses were conducted to evaluate 
the diagnostic validity of MoCA total score in discrimi-
nating between: (i) cognitively impaired MS group and 
cognitively intact MS group; (ii) cognitively impaired 
MS group and control group; and (iii) cognitively 
impaired MS group and unimpaired group (comprising 
the control group and the cognitively intact MS group). 
Additionally we investigated an EM-MoCA-Subscore 
which includes scores of executive functions, visuospa-
tial, short-term memory and temporal and spatial orien-
tation domains, with a range from 0 to 19 points. We 
found statistically significant differences in the 
EM-MoCA-Subscore (F(1,55) ¼ 21.458, p < 0.001, 
g2p ¼ 0:281) between the cognitively intact (16.62 �
1.17) and cognitively impaired MS group (14.21 � 1.82), 
considering the control for the effect of covariates (age 
and educational level). ROC curve analyses were 
computed to investigate the diagnostic accuracy of 
EM-MoCA-Subscore in discriminating between: (i) cog-
nitively impaired MS group and cognitively intact MS 
group; (ii) cognitively impaired MS group and control 
group; and (iii) cognitively impaired MS group and 
unimpaired group (comprising the control group and 
the cognitively intact MS group). 
All AUC values, optimal cut-off points (according to 
the Youden index) and respective sensitivity, specificity, 
PPV, NPV, and accuracy values are presented in the 
Table 5. 
Discussion 
To date, there have been few validation studies of the 
MoCA for the detection of cognitive impairment in 
MS patients (Abraham & Rege, 2012; Aksoy et al., 
Table 5. Cut-off points and diagnostic validity.  
Groups AUCs Cut-off Sensitivity Specificity PPV NPV Accuracy  
MoCA Total Score Impaired MS vs Intact MS  0.837 (CI ¼ 0.736–0.937) <26 76 73 78 70 75 
Impaired MS vs Control  0.833 (CI ¼ 0.751–0.914) <26 76 59 66 70 68 
Impaired MS vs Unimpaired  0.834 (CI ¼ 0.760–0.907) <26 76 77 56 89 76 
EM-MoCA-Subscore Impaired MS vs Intact MS  0.871 (CI ¼ 0.784–0.958) <17 94 87 76 97 89 
Impaired MS vs Control  0.844 (CI ¼ 0.767–0.921) <17 94 41 57 89 65 
Impaired MS vs Unimpaired  0.852 (CI ¼ 0.783–0.922) <17 94 52 49 95 66 
Note. MoCA: Montreal Cognitive Assessment (maximum score ¼ 30); EM-MoCA-Subscore: composed by executive functions, visuospatial, short-term memory 
and orientation domains (maximum score ¼ 19); Unimpaired group comprise the Control group and the Intact MS group; AUC: area under the operating 
characteristic curve; PPV: positive predictive value; NPV: negative predictive value. 
Sensitivity, Specificity, PPV, NPV, and Classification Accuracy values were expressed in percentage. 
Cut-off values indicate the minimum score required for absence of signal.   
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2013; Dagenais et al., 2013; Kaur et al. 2013). Although 
these studies consensually pointed out the usefulness 
and validity of the instrument, none of them fully exam-
ined the discriminative validity of the test, nor was the 
diagnostic accuracy of the MoCA to detect CD in MS 
using cut-off points clearly defined. Thus, the aim of 
the present study was to carry out a deeper and more 
consistent investigation of the utility of the MoCA’s 
Portuguese version to screen for CD in MS patients. 
For this purpose, several analyses were conducted in 
order to examine the psychometric properties of the 
MoCA, the influence of sociodemographic variables 
on its performance and the cognitive performances of 
MS patients, and to determine the optimal cut-off point 
for detecting cognitive impairment in these patients and 
the respective diagnostic accuracy. 
The results of this study indicate that the MoCA is a 
psychometrically valid screening instrument for the 
detection of MS-related cognitive impairment. The 
MoCA displayed adequate overall psychometric charac-
teristics when used to assess MS patients, as indicated by 
good indicators of convergent validity. Our results 
showed coefficient alpha for the MoCA slightly lower 
than 0.70, which can lead to question whether it has 
an acceptable reliability. Although the Cronbach’s alpha 
is the most commonly used measure of internal consist-
ency, psychometricians have pointed out limitations of 
coefficient alpha as a measure of reliability, as well as 
recurrent misinterpretations. In this context, it should 
be noted that higher reliability may indicate undue nar-
rowness of content or item redundancy that can limit 
predictive utility (according to attenuation paradox: 
Loevinger, 1954). For this reason, some authors dis-
puted the view that alpha should necessarily be above 
.70 (e.g., Schmitt, 1996) and others cautioned against 
alphas greater than .90 (e.g., Streiner, 2003). 
Additionally, the significant positive correlation 
coefficients found between each item and its respective 
cognitive domain (all of the items were more strongly 
correlated with their own respective domain than with 
any other) and between cognitive domains and the 
MoCA total score (each cognitive domain was more 
strongly correlated with the MoCA total score than with 
any other domain) support both the MoCA’s construct- 
related validity and the discriminative power of the 
cognitive domains. These results are congruent with 
previous studies conducted with the MoCA in the 
Portuguese population (Freitas, Simões, Marôco, et al., 
2012). 
The MLR analyses highlighted the significant influ-
ence of MFIS and TeLPI scores on MoCA performance 
in MS patients, reflecting the positive impact of premor-
bid intelligence and the negative impact of fatigue on 
cognitive functioning of MS patients. In contrast, age, 
education level and BDI had no significant contribution 
to the regression model. The premorbid intelligence, 
along with age and education, has been identified as a 
major predictor of cognitive performance in screening 
tests such as MMSE scores (Christensen & Jorm, 1992; 
Star & Lonie, 2007). More specifically, Alves, Simões, 
Martins, Freitas, and Santana (2013) demonstrated that 
premorbid intelligence influences the MMSE and the 
MoCA scores in both cognitively healthy participants 
and patients with cognitive impairment (mild cognitive 
impairment and Alzheimer disease), and proposed that 
a premorbid intelligence measure should be considered 
to ensure correct interpretation of scores. 
In this study, the prevalence of cognitive impairment 
in patients with MS was 56%, and although the reported 
frequency of cognitive impairment in MS varies widely, 
our findings are in line with studies describing a high 
prevalence (Amato et al., 2006). Moreover, it is also 
noteworthy that cognitively impaired MS patients pre-
sented similar age of onset, age at diagnosis, time taken 
to establish a diagnosis, disease duration, physical 
disability measured by the EDSS and depressive symp-
tomatology as measured by the BDI compared to cogni-
tively intact MS patients, suggesting that cognitive 
dysfunction may occur in all disease stages and be dis-
sociated from physical disability. Finally, patients with 
cognitive impairment presented higher scores for fati-
gue, as measured by the MFIS. Fatigue is a prominent 
symptom in MS and its relation with cognitive impair-
ment is still a matter of debate. While some studies indi-
cated that fatigue can impair cognitive functioning in 
MS (Krupp & Elkins, 2000), others revealed that there 
is no direct association between fatigue and actual cog-
nitive performance (Parmenter, Denney, & Lynch, 
2003). Moreover, the nature of this potential association 
remains unknown. It may be hypothesized that either 
cognitive dysfunction causes fatigue by producing acti-
vation of compensatory pathways or fatigue contributes 
to a poorer performance in cognitive tasks. 
The analyses of group differences highlight the 
MoCA’s discriminative capacity. In fact, total scores 
were able to efficiently distinguish: (i) all three groups: 
cognitively impaired MS group, cognitively intact MS 
group and control group; (ii) the clinical from the 
control group, (iii) the cognitively intact from the cog-
nitively impaired MS patients, and (iv) the cognitively 
impaired MS patients from the control group, with large 
effect sizes according to Cohen (1988). Furthermore, 
when we analyzed the MoCA’s cognitive domains, stat-
istically significant differences were systematically 
observed in the executive functions and memory 
domains in all above subgroups’ comparisons 
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established. These findings are convergent with findings 
that have been reported in the literature (Abraham & 
Rege, 2012; Aksoy et al., 2013), with one exception: in 
the current study, no differences were found in the 
attention domain. Overall, the cognitively impaired 
MS patients showed a statistically significant poor per-
formance in the executive functions, visuospatial, 
short-term memory and orientation domains when 
compared with cognitively intact MS patients and 
statistically significant lower scores in the executive 
functions, short-term memory and orientation domains 
than the healthy control subjects. On the other hand, 
when comparing the cognitively intact MS patient 
group with the control group, we did not find any stat-
istically significant differences in MoCA total scores or 
any of the MoCA’s cognitive domains, suggesting a 
similar cognitive performance. 
Regarding the results obtained with the comprehen-
sive and holistic battery of tests used in this study, there 
were significant differences between the cognitive pro-
files of the MS patients and those of the healthy control 
subjects. As expected, premorbid intelligence levels were 
comparable, and in addition similar performances were 
observed in the VFT and RAPM tests. Concerning other 
neuropsychological measures of the battery, the MS 
group showed a statistically significant lower perfor-
mance than the control group in all instruments. Since 
the performances on these instruments were used to 
classify the cognitive state of MS patients as cognitively 
intact or cognitively impaired, it is not methodologically 
correct to compare the performances of the MS 
subgroups in the comprehensive neuropsychological 
assessment battery. 
Several ROC curve analyses were conducted to 
evaluate the diagnostic validity of MoCA total score 
and EM-MoCA-Subscore in discriminating between: 
(i) cognitively impaired MS group and cognitively intact 
MS group; (ii) cognitively impaired MS group and con-
trol group; and (iii) cognitively impaired MS group and 
unimpaired group (comprising the control group and 
the cognitively intact MS group). The optimal cut-off 
point for the MoCA total score for identifying CD in 
MS patients, allowing maximum sensitivity and speci-
ficity, was below 26 points. For example, between the 
cognitively impaired and intact MS patients it showed 
good sensitivity (76%), specificity (73%), PPV (78%), 
NPV (70%), and classification accuracy (75%). These 
diagnostic accuracy parameters are improved with the 
EM-MoCA-Subscore, which only includes the MoCA’s 
cognitive domains with more discriminative power 
between the cognitively impaired MS patients and 
unimpaired participants (executive functions, visuospa-
tial, short-term memory, and temporal and spatial 
orientation domains), thus enhancing their sensitivity 
to cognitive impairment. Considering this EM-MoCA- 
Subscore, it was possible to observe an increase of dis-
criminative capacity between the cognitively intact and 
cognitively impaired MS patients, as indicated by the 
higher effect size (MoCA total scores: g2p ¼ 0:217 and 
EM-MoCA-Subscore: g2p ¼ 0:281) and AUC of ROC 
curves (MoCA total scores: AUC ¼ 0.837, 95% CI ¼
0.736–0.937; EM-MoCA-Subscore: AUC ¼ 0.871, 95% 
CI ¼ 0.784–0.958). For a maximum possible score of 
19 points, the optimal cut-off point for the 
EM-MoCA-Subscore for identifying CD in MS patients, 
according to the Youden index, was below 17 points 
(Sensitivity ¼ 94%; Specificity ¼ 62%; PPV ¼ 76%; 
NPV ¼ 89%; Classification Accuracy ¼ 80%). These 
results suggest that the effectiveness of MoCA, parti-
cularly the EM-MoCA-Subscore, as a screen for cogni-
tive impairment in MS is roughly equal to that of 
other recognized screening tests. For instance, SDMT 
revealed a sensitivity of 82%, specificity of 60%, PPV 
of 71%, and NPV of 73%, for a cut-off of 55 (Parmenter, 
Weinstock-Guttman, Garg, Munschauer, & Benedict, 
2007). 
In our opinion, the strengths of the current study 
include 1) the homogeneity of the samples in terms of 
group size, gender, age, and educational level, which 
allowed for a clearer analysis and minimized the influ-
ence of individual and methodological variables; 2) the 
aforementioned rigorous methodological procedures, 
which included the previous well-validated clinical diag-
nosis of the MS group by a multidisciplinary team using 
standard criteria and based on a full investigation; 3) the 
subdivision of the MS group into cognitively intact or 
cognitively impaired patients, according to their 
performance in the comprehensive neuropsychological 
assessment battery, and considering strict criteria for 
classification; 4) the well-characterized control group, 
composed of cognitively healthy adult members of the 
community; and 5) the reduction of inter-rater varia-
bility due to all participants being assessed by the same 
psychologist with expertise in neuropsychological 
assessment. However, some limitations and caveats of 
the current study must be addressed: 1) the small 
sample size; 2) the diagnostic utility must be understood 
in the context of a matched case-control study design 
and the inherent heterogeneity to MS; 3) the fatigue is 
a common symptom in MS patients that may influence 
the cognitive performance during the neuropsychologi-
cal assessment; 4) although the final version of the 
Portuguese MoCA emerged as the result of a rigorous 
process that followed the methodological guidelines 
for cultural adaptation studies, and maximum equival-
ence between the original instrument and the final 
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version of the Portuguese MoCA was sought (Freitas 
et al., 2010), caution should be exercised in generalizing 
these results to other target populations; and 5) there 
are no other validation studies with which the results 
of our research can be compared, namely at the levels 
of diagnostic accuracy of the MoCA total score and 
respective cut-off point; at this level and in relation to 
the EM-MoCA-Subscore corroborative studies are 
needed in future studies. 
In conclusion, the present validation study produced 
several findings that demonstrate that the MoCA is a 
psychometrically valid and sensitive instrument to 
identify the MS-related cognitive impairment. The 
MoCA is a widely accepted tool requiring no specialist 
equipment or specialist expertise, which makes it an 
alternative screening method eventually more easy to 
use in everyday practice given its widespread use and 
international recognition and acceptance. However, 
the MoCA, like the other screening instruments, is 
not a substitute for a more comprehensive assessment 
and should be used to identify patients who may benefit 
from a more thorough assessment or need treatment. 
The multidimensional structure of the MoCA and its 
potential to firstly identify impaired cognitive domains 
can be useful in a context of cognitive inter-patient 
variability insofar as it provides information that may 
be relevant for planning a more comprehensive neurop-
sychological assessment. Finally, we propose the use of 
the EM-MoCA-Subscore for identifying the MS-related 
cognitive impairment, which can reduce administration 
time for cognitive screening in clinical settings and 
potentiate the discriminative power. 
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